Journal article · 2022 · Open access

Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis

Ismaeel U. Yunusa, Nazia Rashid, George Demos, B Mahadik, Victor Abler, Krithika Rajagopalan

Advances in Therapy, 39(5), 1993–2008 · Published 5 March 2022 · DOI 10.1007/s12325-022-02075-8

Open PDFView at the publisherCite this paper

In brief

“Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis” is a 2022 journal article by Ismaeel U. Yunusa and 5 co-authors, published in Advances in Therapy. OpenAlex counts 45 citations as of 20 November 2026, which puts it in the top 6% of works published in 2022 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Advances in Therapy.

Citations
45
Most cited in
2025 (14)
Field-weighted impact
4.24
References
72
Authors
6

Abstract

INTRODUCTION: Dementia-related psychosis (DRP) is characterized by hallucinations and delusions, which may increase the debilitating effects of underlying dementia. This network meta-analysis (NMA) evaluated the comparative efficacy, safety, and acceptability of atypical antipsychotics (AAPs) commonly used off label to treat DRP. METHODS: We included 22 eligible studies from a systematic literature review of AAPs (quetiapine, risperidone, olanzapine, aripiprazole, and brexpiprazole) used off label to treat DRP. Study outcomes were: (1) efficacy-neuropsychiatric inventory-nursing home (NPI-NH psychosis subscale), (2) safety-mortality, cerebrovascular events (CVAEs), and others (somnolence, falls, fractures, injuries, etc.), and (3) acceptability-discontinuations due to all causes, lack of efficacy, and adverse events (AEs). We used random-effects modeling to estimate pooled standardized mean differences (SMDs) for NPI-NH psychosis subscale scores and odds ratios (OR) for other dichotomous outcomes, with their respective 95% confidence intervals (CIs). RESULTS: Compared with placebo, aripiprazole (SMD - 0.12; 95% CI - 0.31, 0.06), and olanzapine (SMD - 0.17; 95% CI - 0.04; 0.02) demonstrated small, non-significant numerical improvements in NPI-NH psychosis scores (5 studies; n = 1891), while quetiapine (SMD 0.04; 95% CI - 0.23, 0.32) did not improve symptoms. The odds of mortality (15 studies, n = 4989) were higher for aripiprazole (OR 1.58; 95% CI 0.62, 4.04), brexpiprazole (OR 2.22; 95% CI 0.30, 16.56), olanzapine (OR 2.21; 95% CI 0.84, 5.85), quetiapine (OR 1.68; 95% CI 0.70, 4.03), and risperidone (OR 1.63; 95% CI 0.93, 2.85) than for placebo. Risperidone (OR 3.68; 95% CI 1.68, 8.95) and olanzapine (OR 4.47; 95% CI 1.36, 14.69) demonstrated significantly greater odds of CVAEs compared to placebo. Compared with placebo, odds of all-cause discontinuation were significantly lower for aripiprazole (OR 0.71; 95% CI 0.51, 0.98; 20 studies; 5744 patients) and higher for other AAPs. Aripiprazole (OR 0.5; 95% CI 0.31, 0.82) and olanzapine (OR 0.48; 95% CI 0.31, 0.74) had significantly lower odds of discontinuation due to lack of efficacy (OR 12 studies; n = 4382) compared to placebo, while results for quetiapine and risperidone were not significant. Compared with placebo, the odds of discontinuation due to AEs (19 studies, n = 5445) were higher for olanzapine (OR 2.62; 95% CI 1.75, 3.92), brexpiprazole (OR 1.80; 95% CI 0.80, 4.07), quetiapine (OR 1.25; 95% CI 0.82, 1.91), aripiprazole (OR 1.38; 95% CI 0.90, 2.13), and risperidone (OR 1.41; 95% CI 1.02, 1.94). CONCLUSIONS: Overall results demonstrate that, compared with placebo, quetiapine is not associated with improvement in psychosis in patients with dementia, while olanzapine and aripiprazole have non-significant small numerical improvements. These off-label AAPs (quetiapine, risperidone, olanzapine, aripiprazole, and…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Yunusa, I. U., Rashid, N., Demos, G., Mahadik, B., Abler, V., & Rajagopalan, K. (2022). Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis. Advances in Therapy, 39(5), 1993–2008. https://doi.org/10.1007/s12325-022-02075-8

MLA 9

Yunusa, Ismaeel U., et al. “Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.” Advances in Therapy, vol. 39, no. 5, 2022, pp. 1993–2008. https://doi.org/10.1007/s12325-022-02075-8.

Chicago

Yunusa, Ismaeel U., Nazia Rashid, George Demos, B Mahadik, Victor Abler, and Krithika Rajagopalan. 2022. “Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.” Advances in Therapy 39 (5): 1993–2008. https://doi.org/10.1007/s12325-022-02075-8.

Harvard

Yunusa, I. U. et al. (2022) ‘Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis’, Advances in Therapy, 39(5), pp. 1993–2008. doi:10.1007/s12325-022-02075-8.

IEEE

I. U. Yunusa, N. Rashid, G. Demos, B. Mahadik, V. Abler, and K. Rajagopalan, “Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis,” Advances in Therapy, vol. 39, no. 5, pp. 1993–2008, 2022, doi: 10.1007/s12325-022-02075-8.

BibTeX

@article{yunusa2022comparative,
  title     = {{Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis}},
  author    = {Yunusa, Ismaeel U. and Rashid, Nazia and Demos, George and Mahadik, B and Abler, Victor and Rajagopalan, Krithika},
  journal   = {Advances in Therapy},
  year      = {2022},
  volume    = {39},
  number    = {5},
  pages     = {1993--2008},
  doi       = {10.1007/s12325-022-02075-8},
  url       = {https://doi.org/10.1007/s12325-022-02075-8}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202233
202377
20241111
20251414
20261010

Its field-weighted citation impact is 4.24: it has been cited 4.24 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • dementia-related psychosis
  • atypical antipsychotics
  • off-label drug use
  • quetiapine
  • risperidone
  • olanzapine
  • aripiprazole
  • brexpiprazole

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Yunusa, I. U., Rashid, N., Demos, G., Mahadik, B., Abler, V., & Rajagopalan, K. (2022). Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis. Advances in Therapy, 39(5), 1993–2008. https://doi.org/10.1007/s12325-022-02075-8

How many times has this paper been cited?

45 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Advances in Therapy: sign in and open the PDF from this page.

Who wrote this paper?

Ismaeel U. Yunusa, Nazia Rashid, George Demos, B Mahadik, Victor Abler, Krithika Rajagopalan.

What is the DOI of this paper?

10.1007/s12325-022-02075-8, permanently at https://doi.org/10.1007/s12325-022-02075-8. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.